A nano-enabled cancer-specific ITCH RNAi chemotherapy booster for pancreatic cancer

Nanomedicine: Nanotechnology, Biology, and Medicine

Volumn 11, Issue 2, 2015, Pages 369-377

  de la Fuente, Maria ^a,b   Jones, Marie Christine ^a,c   Santander Ortega, Manuel J ^a,d   Mirenska, Anja ^a,e   Marimuthu, Preethi ^a   Uchegbu, Ijeoma ^a   Schätzlein, Andreas ^a  

^a UNIVERSITY OF LONDON   (United Kingdom)

^b University Hospital of Santiago de Compostela   (Spain)

^c UNIVERSITY OF BIRMINGHAM   (United Kingdom)

^d UNIVERSITY OF CASTILLA LA MANCHA   (Spain)

^e HANNOVER MEDICAL SCHOOL   (Germany)

Author keywords

Dendrimer; Dendriplex; ITCH; P73; Pancreatic Cancer; Polypropylenimine; ShRNA; SiRNA

Indexed keywords

CHEMOTHERAPY; DENDRIMERS; RNA;

DENDRIPLEXES; ITCH; PANCREATIC CANCERS; POLYPROPYLENIMINE; SHRNA; SIRNA;

DISEASES;

DAB AM 16; DENDRIMER; GEMCITABINE; SHORT HAIRPIN RNA; SMALL INTERFERING RNA; UBIQUITIN LIGASE ITCH; UBIQUITIN PROTEIN LIGASE; UNCLASSIFIED DRUG; DAB-AM-16; DEOXYCYTIDINE; ITCH PROTEIN, HUMAN; POLYPROPYLENE; REPRESSOR PROTEIN;

ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER INHIBITION; CONTROLLED STUDY; DOWN REGULATION; DRUG SAFETY; HUMAN; HUMAN CELL; IN VITRO STUDY; MULTIPLE CYCLE TREATMENT; PANCREAS CANCER; PROTEIN BINDING; PROTEIN EXPRESSION; RNA INTERFERENCE; ANALOGS AND DERIVATIVES; ANTAGONISTS AND INHIBITORS; APOPTOSIS; BIOSYNTHESIS; CELL PROLIFERATION; CHEMISTRY; DRUG EFFECTS; DRUG RESISTANCE; GENE EXPRESSION REGULATION; GENETICS; PANCREATIC NEOPLASMS; PATHOLOGY; TUMOR CELL LINE;

APOPTOSIS; CELL LINE, TUMOR; CELL PROLIFERATION; DEOXYCYTIDINE; DRUG RESISTANCE, NEOPLASM; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; PANCREATIC NEOPLASMS; POLYPROPYLENES; REPRESSOR PROTEINS; RNA INTERFERENCE; UBIQUITIN-PROTEIN LIGASES;

EID: 84922768824     PISSN: 15499634     EISSN: 15499642     Source Type: Journal    
DOI: 10.1016/j.nano.2014.09.010     Document Type: Article

References (50)

1. WHO World Cancer Report 2014 2014, IARC Nonserial Publication, Geneva. B.W. Stewart, C.P. Wild (Eds.).
2. Ghaneh P., Costello E., Neoptolemos J.P. Biology and management of pancreatic cancer. Gut 2007, 56(8):1134-1152.
3. National Comprehensive Cancer Network Pancreatic Adenocarcinoma 2013, National Comprehensive Clinical Cancer Network, Fort Washington.
4. NICE Technology Appraisal No. 25. Guidance on the use of gemcitabine for the treatment of pancreatic cancer 2004, National Institute for Clinical Excellence, London. Excellence NIfC (Ed.).
5. Collins I., Workman P. New approaches to molecular cancer therapeutics. Nat Chem Biol 2006, 2(12):689-700.
6. Guttmann D.M., Koumenis C. The heat shock proteins as targets for radiosensitization and chemosensitization in cancer. Cancer Biol Ther 2011, 12(12):1023-1031.
7. Karnak D., Xu L. Chemosensitization of prostate cancer by modulating Bcl-2 family proteins. Curr Drug Targets 2010, 11(6):699-707.
8. Rossi M., De Laurenzi V., Munarriz E., Green D.R., Liu Y.C., Vousden K.H., et al. The ubiquitin-protein ligase Itch regulates p73 stability. EMBO J 2005, 24(4):836-848.
9. Hansen T.M., Rossi M., Roperch J.P., Ansell K., Simpson K., Taylor D., et al. Itch inhibition regulates chemosensitivity in vitro. Biochem Biophys Res Commun 2007, 361(1):33-36.
10. Flores E.R., Tsai K.Y., Crowley D., Sengupta S., Yang A., McKeon F., et al. p63 and p73 are required for p53-dependent apoptosis in response to DNA damage. Nature 2002, 416(6880):560-564.
11. Muller P.A., Vousden K.H. p53 mutations in cancer. Nat Cell Biol 2013, 15(1):2-8.
12. Bell H.S., Dufes C., O'Prey J., Crighton D., Bergamaschi D., Lu X., et al. A p53-derived apoptotic peptide derepresses p73 to cause tumor regression in vivo. J Clin Invest 2007, 117(4):1008-1018.
13. Fire A., Xu S., Montgomery M.K., Kostas S.A., Driver S.E., Mello C.C. Potent and specific genetic interference by double-stranded RNA in Caenorhabditis elegans. Nature 1998, 391(6669):806-811.
14. Plumb J.A., Milroy R., Kaye S.B. Effects of the pH dependence of 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyl-tetrazolium bromide-formazan absorption on chemosensitivity determined by a novel tetrazolium-based assay. Cancer Res 1989, 49(16):4435-4440.
15. Workman P., Aboagye E.O., Balkwill F., Balmain A., Bruder G., Chaplin D.J., et al. Guidelines for the welfare and use of animals in cancer research. Br J Cancer 2010, 102(11):1555-1577.
16. Morton D.B., Griffiths P.H. Guidelines on the recognition of pain, distress and discomfort in experimental animals and an hypothesis for assessment. Vet Rec 1985, 116(16):431-436.
17. Santander-Ortega M.J., de la Fuente M., Lozano M.V., Tsui M.L., Bolton K., Uchegbu I.F., et al. Optimisation of synthetic vector systems for cancer gene therapy - the role of the excess of cationic dendrimer under physiological conditions. Curr Top Med Chem 2014, 14(9):1172-1181.
18. Frechet J.M.J., Tomalia D.A. Dendrimers and other dendritic polymers 2001, Wiley.
19. Novoa-Carballal R., Pergushov D.V., Muller A.H.E. Interpolyelectrolyte complexes based on hyaluronic acid-block-poly(ethylene glycol) and poly-l-lysine. Soft Matter 2013, 9:4297-4303.
20. Kabanov A.V., Bronich T.K., Kabanov V.A., Yu K., Eisenberg A. Soluble stoichiometric complexes from poly(N-ethyl-4-vinylpyridinium) cations and poly(ethylene oxide) block-polymethacrylate anions. Macromolecules 1996, 29(27):6797-6802.
21. Oupický D., Koňák Č., Ulbrich K. Preparation of DNA complexes with diblock copolymers of poly[N(2-hydroxypropyl)methacrylamide] and polycations. Mater Sci Eng C Mater Biol Appl 1999, 7(1):59-65.
22. Perez A.P., Romero E.L., Morilla M.J. Ethylendiamine core PAMAM dendrimers/siRNA complexes as in vitro silencing agents. Int J Pharm 2009, 380(1-2):189-200.
23. Lopez-Leon T., Carvalho E.L.S., Seijo B., Ortega-Vinuesa J.L., Bastos-Gonzalez D. Physicochemical characterization of chitosan nanoparticles: electrokinetic and stability behavior. J Colloid Interface Sci 2005, 283(2):344-351.
24. Casals E., Pfaller T., Duschl A., Oostingh G.J., Puntes V. Time Evolution of the Nanoparticle Protein Corona. ACS Nano 2010, 4(7):3623-3632.
25. Lundqvist M., Stigler J., Elia G., Lynch I., Cedervall T., Dawson K.A. Nanoparticle size and surface properties determine the protein corona with possible implications for biological impacts. Proc Natl Acad Sci U S A 2008, 105(38):14265-14270.
26. Tirado-Miranda M., Schmitt A., Callejas-Fernandez J., Fernandez-Barbero A. The aggregation behaviour of protein-coated particles: a light scattering study. Eur Biophys J 2003, 32(2):128-136.
27. Chisholm E.J., Vassaux G., Martin-Duque P., Chevre R., Lambert O., Pitard B., et al. Cancer-specific transgene expression mediated by systemic injection of nanoparticles. Cancer Res 2009, 69(6):2655-2662.
28. Hillaireau H., Couvreur P. Nanocarriers' entry into the cell: relevance to drug delivery. Cell Mol Life Sci 2009, 66(17):2873-2896.
29. Manunta M., Nichols B.J., Tan P.H., Sagoo P., Harper J., George A.J.T. Gene delivery by dendrimers operates via different pathways in different cells, but is enhanced by the presence of caveolin. J Immunol Methods 2006, 314(1-2):134-146.
30. Perez A.P., Cosaka M.L., Romero E.L., Morilla M.J. Uptake and intracellular traffic of siRNA dendriplexes in glioblastoma cells and macrophages. Int J Nanomedicine 2011, 6:2715-2728.
31. Aagaard L., Rossi J.J. RNAi therapeutics: principles, prospects and challenges. Adv Drug Deliv Rev 2007, 59(2-3):75-86.
32. Zinselmeyer B.H., Mackay S.P., Schatzlein A.G., Uchegbu I.F. The lower-generation polypropylenimine dendrimers are effective gene-transfer agents. Pharm Res 2002, 19(7):960-967.
33. de la Fuente M., Ravina M., Sousa-Herves A., Correa J., Riguera R., Fernandez-Megia E., et al. Exploring the efficiency of gallic acid-based dendrimers and their block copolymers with PEG as gene carriers. Nanomedicine 2012, 7(11):1667-1681.
34. Weitman S., Marty J., Jolivet J., Locas C., Von Hoff D.D. The new dioxolane, (-)-2'-deoxy-3'-oxacytidine (BCH-4556, troxacitabine), has activity against pancreatic human tumor xenografts. Clin Cancer Res 2000, 6(4):1574-1578.
35. Lee S.H., Ryu J.K., Lee K.Y., Woo S.M., Park J.K., Yoo J.W., et al. Enhanced anti-tumor effect of combination therapy with gemcitabine and apigenin in pancreatic cancer. Cancer Lett 2008, 259(1):39-49.
36. Buchsbaum D.J., Bonner J.A., Grizzle W.E., Stackhouse M.A., Carpenter M., Hicklin D.J., et al. Treatment of pancreatic cancer xenografts with Erbitux (IMC-C225) anti-EGFR antibody, gemcitabine, and radiation. Int J Radiat Oncol Biol Phys 2002, 54(4):1180-1193.
37. Redston M.S., Caldas C., Seymour A.B., Hruban R.H., da Costa L., Yeo C.J., et al. p53 Mutations in Pancreatic Carcinoma and Evidence of Common Involvement of Homocopolymer Tracts in DNA Microdeletions. Cancer Res 1994, 54(11):3025-3033.
38. Rödicker F., Pützer B.M. p73 Is Effective in p53-null Pancreatic Cancer Cells Resistant to Wild-type TP53 Gene Replacement. Cancer Res 2003, 63(11):2737-2741.
39. Dufes C., Keith W.N., Bilsland A., Proutski I., Uchegbu I.F., Schatzlein A.G. Synthetic anticancer gene medicine exploits intrinsic antitumor activity of cationic vector to cure established tumors. Cancer Res 2005, 65(18):8079-8084.
40. Kubowicz P., Zelaszczyk D., Pekala E. RNAi in Clinical Studies. Curr Med Chem 2013, 20(14):1801-1816.
41. Rao D.D., Vorhies J.S., Senzer N., Nemunaitis J. siRNA vs. shRNA: similarities and differences. Adv Drug Deliv Rev 2009, 61(9):746-759.
42. Dufes C., Uchegbu I.F., Schatzlein A.G. Dendrimers in gene delivery. Adv Drug Deliv Rev 2005, 57(15):2177-2202.
43. Daka A., Peer D. RNAi-based nanomedicines for targeted personalized therapy. Adv Drug Deliv Rev 2012, 64(13):1508-1521.
44. Hung S.W., Mody H.R., Govindarajan R. Overcoming nucleoside analog chemoresistance of pancreatic cancer: a therapeutic challenge. Cancer Lett 2012, 320(2):138-149.
45. Marechal R., Bachet J.B., Mackey J.R., Dalban C., Demetter P., Graham K., et al. Levels of gemcitabine transport and metabolism proteins predict survival times of patients treated with gemcitabine for pancreatic adenocarcinoma. Gastroenterology 2012, 143(3):664-674. [e1-6].
46. Koay E.J., Truty M.J., Cristini V., Thomas R.M., Chen R., Chatterjee D., et al. Transport properties of pancreatic cancer describe gemcitabine delivery and response. J Clin Invest 2014, 124(4):1525-1536.
47. Zhang Y., Peng L., Mumper R.J., Huang L. Combinational delivery of c-myc siRNA and nucleoside analogs in a single, synthetic nanocarrier for targeted cancer therapy. Biomaterials 2013, 34(33):8459-8468.
48. Zhao X.Y., Nie C.L., Liang S.F., Yuan Z., Deng H.X., Wei Y.Q. Enhanced gemcitabine-mediated cell killing of human lung adenocarcinoma by vector-based RNA interference against PLK1. Biomed Pharmacother 2012, 66(8):597-602.
49. Wonganan P., Chung W.G., Zhu S., Kiguchi K., Digiovanni J., Cui Z. Silencing of ribonucleotide reductase subunit M1 potentiates the antitumor activity of gemcitabine in resistant cancer cells. Cancer Biol Ther 2012, 13(10):908-914.
50. Bellomaria A., Barbato G., Melino G., Paci M., Melino S. Recognition mechanism of p63 by the E3 ligase Itch: novel strategy in the study and inhibition of this interaction. Cell Cycle 2012, 11(19):3638-3648.